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Objective To investigate the association between cigarette smoking and the risk of developing 
pancreatic cancer and if there are any differences in risk between male- and female smokers. 
We also aimed to see if there is scientific consensus among recent expert reports (2013-2017) 
on smoking and pancreatic cancer. 
 
Methods For our statistical analysis, we used data from 83 500 participants born between 
1905 and 1968, recruited from the Norwegian Counties Study (NCS) during the survey 
periods of 1974-1988. The end of follow-up was Dec. 2013 and participants were followed 
through national registries in terms of cancer-diagnosis, death, emigration and other end-
points. Cox proportional hazards model was used to obtain age-adjusted and multivariate 
hazard ratios with 95% confidence intervals for obtaining risk estimates for smoking and 
levels of smoking exposure. The multivariate analysis included the covariates; age, education 
level, body mass index and physical activity level. 
 
Results In the age adjusted analysis, smoking was associated with a significant increased risk 
of pancreatic cancer for ever smokers compared with never smokers for both men (HR = 2.54, 
95% CI = 1.92-3.34) and women (HR = 2.44, 95% CI = 1.68-3.54). In multivariate analysis, 
the overall smoking associated risk of pancreatic cancer compared with never smokers for 
both sexes were similar to that of the age adjusted analysis. For male smokers, the different 
measured smoking exposure variables (age at smoking-initiation, cigarettes per day, total 
years of smoking and pack years), total years of smoking had the strongest association for 
ever- compared with never smokers (HR = 2.82, 95% CI = 1.87-4.24). For female smokers, 
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early smoking initiation (≤ 19 years) had the strongest association (HR = 3.28, 95% CI = 
2.22-4.82). Female smokers showed linear trends (Ptrend < 0.05) across the different smoking 
exposure categories (age at smoking-initiation, cigarettes per day, total years of smoking and 
pack years). For male smokers, there was no observed linear trend for any of the 
corresponding exposure categories (Ptrend > 0.05). 
 
Conclusion In support of similar previous research, our findings conclude that there is a 
significant increased risk of pancreatic cancer associated with cigarette smoking. 
Furthermore, we find that female smokers have a dose-response relationship between 
smoking and pancreatic cancer risk, which was not evident for male smokers. 
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Pancreatic cancer is considered one of the deadliest types of cancer as it often 
produces little or no symptoms in the early staged of the disease. It is usually discovered after 
it has metastasized to other organs, and there are often limited treatment options available. 
Given the poor prognosis of the disease, steps should be taken to prevent future cases of 
pancreatic cancer through identification and prevention the of risk factors associated with the 
disease.  
 
 There are certain risk factors that through research have been associated with the 
development of pancreatic cancer: Risk factors based on behaviour/lifestyle (risk factors that 
can be changed), risk factors that are based on hereditary factors, health situation (risk factors 
that cannot be changed), and risk factors that have inconclusive findings when it comes to the 
risk of developing pancreatic cancer. Behavioural risk factors such as smoking have previous 
been linked to approximately 25% of all pancreatic cancer cases (Wolfgang et al, 2013). We 
will examine this relationship further in this thesis. We will compare results from our analysis 
based on data from the Norwegian Counties Study (NCS) with published research that focuses 
on the association between smoking and pancreatic cancer published after inclusion ended 
(2012) for the Surgeon General’s Report of 2014 – 50 years of progress. The Surgeon 
General’s Report is one of the leading expert report on cancer and smoking as a risk. 
However, pancreatic cancer was not included in any large part. We will therefore examine 
















2. Objective of the thesis 
 
This thesis aims to examine if cigarette smoking increases the risk of developing 
pancreatic cancer and if this association differs between male- and female smokers. To 
achieve this, we will examine relevant cohort studies regarding smoking and pancreatic 
cancer risk that has been published since 2013, and compare these findings to our own results 
from the statistical analysis based on the Norwegian Counties Study/Fylkesundersøkelsen for 





2.1.  Null hypothesis 
• Null-hypothesis 1 (1H0): There is no association between cigarette smoking and the 
risk of developing pancreatic cancer. 
• Alternate-hypothesis 1 (1Ha0): There is an association between cigarette smoking and 
the risk of developing pancreatic cancer. 
• Null-hypothesis 2 (2H0): There is no difference in the risk of developing pancreatic 
cancer between male- and female smokers. 
• Alternate-hypothesis 2 (2Ha0): There is a difference in risk of developing pancreatic 
cancer between male- and female smokers. 
 
2.2.  Research questions  
In addition to the null hypothesis, we have developed the following research questions 
that we aim to answer with this thesis: 
 
- Is there scientific consensus across the recent expert reports from 2013-2017 (after 
inclusion of the Surgeon General’s Report) as to the adverse effects of smoking and 
pancreatic cancer?  
 
- Do any of the possible confounders in the acquired dataset modify the exposure from 






3.  Background and theory 
 
3.1. Pancreatic cancer; incidence, risk factors, treatment and survival. 
3.1.1.  Introduction to the disease. 
The pancreas is one of the largest digestive glands in our body, and is located posterior 
to the stomach in the upper left part of the abdomen and stretches from the curve of the 
duodenum and extends transversely across the retroperitoneum. Major blood vessels including 
the superior mesenteric vein and artery, the portal vein and the celiac axis surround the 
pancreas and provides the necessary blood supply (Rela & Reddy, 2016). 
 
The two main functions of the pancreas are to help with digestion through the 
production of digestive enzymes, and the production of hormones that affect the metabolism 
but also the secretion of other hormones; insulin being one of the most common known. The 
digestive function of the pancreas is known as the “exocrine” function while the hormonal 
function is known as the “endocrine” function, of which the exocrine tissue mass is forming 
98% of the pancreatic tissue and the endocrine pancreatic islets (or islets of Lagerhans), are 
embedded within (Rela & Reddy, 2016). The exocrine pancreatic glands produce enzymes 
such as amylase, that helps with the digestion of carbohydrates, lipase which contributes to 






These enzymes among others are released as part of the pancreatic juices through a 
series of canals or ducts that culminate in the main pancreatic duct (ductus pancreaticus) 
which joins the common bile duct (ductus choledocus) to form the ampulla of Vater (ampulla 
vaterii) located at the duodenum (Rela & Reddy, 2016).  
 
The endocrine pancreatic islets consist of at least four different cell-types, which 
includes insulin-producing β-cells, glucagon-producing α-cells, somatostatin-producing δ-
cells and pancreatic polypeptide-producing PP-cells. The total cell population is mainly 
comprised of β-cells (insulin producing) 60-80% and α-cells (glucagon-producing) 15-20%. 
(Campbell & Verbeke, 2013).  
 
Figure 1: Anatomical illustration of pancreas location, blood supply and sections. 
 





Pancreatic cancer or carcinomas can be classified into two main categories depending 
in which cellular type the cancer originates, either exocrine or endocrine. The symptoms, 
prognosis, risk factor and causes for each type of pancreatic carcinoma will differ depending 
on what type of tumor is present. The National Cancer Institute (NCI) defines a tumor to be 
either benign or malign; in which benign tumors does not invade nearby cell tissue and rarely 
grows back after being surgically removed. Malignant tumors can invade nearby tissue and 
spread to other parts of the body, and may also reappear (recidivism) even after being 
surgically removed (NCI, 2015).  
 
Because of the deep location of the pancreas, most tumors that develops in the 
pancreatic tissue will not be palpable and symptoms will in most cases first appear after the 
cancer have either grown large enough or started interfering with the surrounding organs; 
stomach, spleen, duodenum, liver or gallbladder which implies that the symptoms are rarely 








3.1.1.1.  Exocrine pancreatic cancers 
Adenocarcinomas accounts for about 95% of all the exocrine pancreatic cancers (ACS, 
2016) and is defined as a malignant tumor that originates in a glandular epithelium. “Adeno” 
meaning “pertaining to a gland” and “carcinoma” meaning cancer (Mandal, 2013). The most 
common types of pancreatic carcinomas originate from the ductular cells and is often referred 
to as ductal adenocarcinomas. They account for approximately 75-90% of all primary 
pancreatic adenocarcinomas (Lack, 2003). 
 
Less common types of exocrine pancreatic cancers include squamous cell carcinomas, 
signet ring cell carcinomas, adenosquamous carcinoma and giant cell undifferentiated 
carcinomas and ampullary cancer (ACS, 2016). Ampullary cancer (carcinoma of the ampulla 
of Vater) are not technically defined as a type of pancreatic cancer, but they are treated very 
similarly, and also affect the bile ducts. They often produce symptoms at an early stage, 
which gives them a better prognosis than other pancreatic cancers (ACS, 2016).  
 
3.1.1.2.   Endocrine pancreatic cancers 
Neuroendocrine tumors of the pancreas (NETs) or islet cell carcinomas accounts for 
the remaining 5% of pancreatic cancers. Approximately 75% of all neuroendocrine tumors are 
producing symptoms that can be related to the hormone peptides produced by the endocrine 
cells; either gastrin, insulin, glucagon, somatostatin, vasoactive intestinal peptide or 





Approximately 50% of all gastrinomas are malignant, most glucagonomas, 
somatostatinomas, VIPomas (vasoactive intestinal peptide) and PPomas (pancreatic 
polypeptide) are malign and cancerous, while most insulinomas are benign. The most 
functioning NETs are either gastrinomas or insulinomas (ACS, 2016). The remaining 25% of 
NETs are non-functioning, meaning that they do not produce enough excess hormones to 
cause symptoms in the patient (Beger, et al, 2015). 
 
3.1.2.  Incidence of pancreatic cancer 
The incidence of pancreatic cancer varies geographically with the highest incidence 
reported in GLOBOCAN 2012 being, Northern America (7.4 per 100.000) and Western 
Europe (7.3 per 100.000) and the lowest observed rate in Middle Africa and South-Central 
Asia (about 1 per 100.000). The highest rate of pancreatic cancer is seen in Czech Republic 
(9.7 per 100.000) and the lowest incidence is seen in Pakistan (0.5 per 100.000) (Ferlay, et al., 
2014). This variation can be influenced by a difference in the diagnostic accuracy and 
reporting between countries (Ferlay, et al., 2013) as well as differences in exposure to 
different risk factors. There is also a gender-based variation in the incidence rate of pancreatic 
cancer, whereas men have a higher incidence (4.9 per 100.000) than woman (3.6 per 100.000) 
(Ferlay, et al., 2015), this is likely explained predominantly by differences in exposure to 





The incidence rate of pancreatic cancer in western societies increases with age, 
regardless of gender, and is highest in individuals above 70 years of age, and more than 90% 
of all cases of pancreatic cancer is diagnosed in individuals above the age of 65, according to 
the American Cancer Society (ACS, 2016). The statistics from the Surveillance, 
Epidemiology and End Results (SEER) registries in the United States, shows that pancreatic 
cancer is predominantly a disease of the elderly (aged ≥ 65 years), although the risk increases 
significantly with age, pancreatic cancer can affect anyone at any age, as seen in figure 2. 
 
Figure 2: Percentage of new cases of pancreatic cancer according to age for both sexes and 
all races. 





3.1.2.1. Lifetime risk and Norwegian statistics 
The lifetime risk of developing pancreatic cancer is about 1.5% regardless of gender 
and with an estimated 331.000 deaths per year in 2012 (Ferlay, et al., 2015) pancreatic cancer 
remains a fairly common malignant neoplasm, and is one of the leading causes of cancer 
mortality in the developed world. With a recorded 736 new cases in 2014 and incidence rates 
of 15.3 and 13.5 per 100.000 for men and women respectively, pancreatic cancer is a 
relatively rare cancer type in Norway. However, due to its poor prognosis of survival, it is 
ranked the fourth most deadly malignant neoplasm in Norway, accountable for about 713 
deaths in 2014 (Cancer Registry in Norway, 2015; Larsen, Møller, Johannessen, Larønningen, 
2015).  These numbers are seen to be relatively stable for men, but somewhat rising for 
women the last 40 years (figure 3). 
 
Figure 3: Pancreatic cancer statistics for Norway 1965-2012. 





The estimated 5-year prevalence of people in the world living with pancreatic cancer is 
4.1 per 100.000 (World Cancer Research Fund International, n.d), and the 5-year prevalence 
for Europe is 10.2 per 100.000 and 7.0 per 100.000 for Norway as off 2012 (World Health 
Organization, n.d). 
 
3.1.3.   Risk factors for the development of pancreatic cancer  
According to the Dictionary of Epidemiology by M. Porta (2014), a risk factor is an 
aspect of personal behaviour or lifestyle, exposure through environment or a genetic 
characteristic that can be associated with health or health related condition(s), based on the 
scientific evidence.  Risk factors can be classified as modifiable- non-modifiable- or unclear 
risk effects. 
 
3.1.3.1.  Modifiable risk factors 
Modifiable risk factors are determinants that can be modified by intervention or 
behavioural/lifestyle choices, and thus reducing the probability for the disease (Burt, 2001). 
 
3.1.3.1.1.  Tobacco smoking 
Tobacco smoking is the most important of all the modifiable risk factors for pancreatic 
cancer, and active smokers have been reported to having as much as 75% increased risk of 
pancreatic cancer compared with never smokers (Iodice, Gandini, Maisonneuve, & 
Lowenfels, 2008). Evidence from meta-analysis comprising of 30 retrospective, and 12 
prospective studies (Zou, et al., 2014) indicates that cigarette smoking having a non-linear 
dose-response relationship between pancreatic cancer risk and duration of smoking, 
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cumulative amount of cigarettes, time since quitting and intensity, which increased up to a 
“moderate” consumption (25-30 cigarettes per day) then levelling off at higher intensities. 
The same association is also observed in form of risk reduction from smoking cessation. 
Iodice, Gandini, Maisonneuve, & Lowenfels (2008) reported that smoking cessation started to 
reduce the increased risk from smoking after a cessation period of  ≥10 years, Schulte, et al. 
(2014) reported that the risk levels returned to baseline after approximatly 20 years of 
abstinense and that smoking intesity was of less importance than that of smoking duration or 
time since quitting. 
 
 Some studies have also found that there is a possible difference in the effect size of 
pancreatic cancer risk from smoking intensity between sexes whereas women have a higher, 
though non-significant effect size (Zou, et al., 2014; Nakamura, et al., 2011 & Duell, Holly, 
Bracci, Liu, Wiencke, & Kelsey, 2002). 
 
3.1.3.1.2.  Overweight and obesity 
Being overweight or obese has been reported to increase the risk of pancreatic cancer 
and also the reduction of survival for patients with pancreatic cancer: Overweight measured in 
kg/m2 (BMI) has been associated with an increased risk of pancreatic cancer, and results from 
meta-analysis shows that high BMI yields a multivariate relative risk of 1.55 (1.9-2.03 95% 
CI) for individuals with a high BMI (≥35 kg/m2) compared with individuals with normal BMI 





Genkinger and colleagues (2011) also showed a linear relationship between baseline 
BMI (21-22.9 kg/m2) and pancreatic adenocarcinoma risk (multivariate relative risk = 1.14) 
for 5kg/m2 increment. Parkin, Boyd & Walker (2011) estimated that overweight and obesity 
was attributable for 12.2% of all pancreatic cancer incidence cases in the UK in 2010. Waist-
to-hip measurement of abdominal obesity has also been linked to pancreatic cancer mortality, 
showing an increased relative risk (RR) of 1.07 (1.02-1.17 95% CI) per 10cm increment after 
adjustments for BMI (Genkinger, et al., 2015).  
 
The underlying mechanisms which explain the association between obesity and 
pancreatic cancer are hypothesized to be linked to; hormonal and inflammatory effects of 
adipose tissue, i.e. obesity and high BMI has been associated to with increased insulin and C-
peptide circulation, hyperglycaemia, insulin resistance and diabetes mellitus; increased 
exposure to carcinogens as a result of increased food consumption and; diminished physical 
activity (Bracci, 2012). Some studies have also reported an association with blood glucose 
levels prior to diagnosis and pancreatic cancer risk (Batty, Shipley, Marmot, & Smith, 2004; 





3.1.3.1.3.  Exposure to certain chemicals 
Exposure to certain types of chemical has also been thought to increase the risk of 
pancreatic cancer. In a clinic-based, case–control study Antwi, et al. (2015) found evidence 
from multivariate regression (controling for age, sex, smoking, diabetes, bmi and education 
status) that suggests that regular exposure to different chemicals might increase the risk of 
pancreatic cancer; pesticides (HR = 1.21, CI = 1.02-1.44), asbestos (HR = 1.34, CI = 1.23-
1.92), benzene (HR = 1.70, CI = 1.23-2.35), and chlorinated hydrocarbons (HR = 1.63, CI = 
1.32-2.02). These findings are consistent with a previous meta-analysis from 2001 on 
chemical exposure that suggest a weak association between Trichloroethylene, Poly-
chlorinated biphenyls (PCB’s), methylene chloride, and vinyl chloride and pancreatic cancer 





3.1.3.2.  Non-modifiable risk factors 
Non-modifiable risk factors are the opposite of modifiable factors, these cannot be 
changed through intervention measures, and will remain a risk factor regardless of 
behavioural/lifestyle choices that are made. 
 
3.1.3.2.1.  Age 
 Age is considered one of the main risk factors for developing cancer as the incidence 
of most cancer-types increases with advancing age. The risk of developing cancer has been 
examined by White et al (2015), and shows a lifetime risk among U.S. citizens of 13,09% and 
17,85% for developing cancer within 10years after being aged 60 and 70 years respectively. 
The risk of developing cancer for Norwegian aged 75 or younger, are 36,2% and 29,5% for 
men and women respectively (Cancer Registry of Norway, 2015). Although age cannot be 
held primary responsible for the development of cancer, it can modify other risk factors such 
as lifestyle and exposure to carcinogens, thus increasing the overall risk of cancer (White et 
al, 2015). For the Norwegian population, cancer is predominately present among those aged 
>50 years according to the Norwegian Cancer Report of 2015, with 91,5% and 85,7% for men 
and women respectively (Larsen, Møller, Johannessen, Larønningen, 2016).  
 
3.1.3.2.2.  Family history / hereditary factors 
 Several genetic syndromes have been linked to an increased risk of developing 
pancreatic cancer. Hereditary breast and ovarian cancer syndrome (HBOC), and particularly 
the BRCA2 mutations and Lynch syndrome have been linked to increased risk of pancreatic 
cancer (Risch, et al., 2006; Lynch, Voorhees, Lanspa, McGreevy, & Lynch, 1985). Peutz-
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Jeghers syndrome has been seen as the genetic disposition with the highest increased lifetime 
risk for the development of pancreatic cancer (Giardiello, et al., 2000), but the syndrome is 
relatively rare, i.e. 1:8000 to 1:200 000 births (Lindor & Greene, 1998). 
 
3.1.3.2.3.  Pancreatitis 
 Patients with either chronic pancreatitis or those threated more than once for either 
acute or unspecified pancreatitis have a 2-fold excess risk of pancreatic cancer compared with 
those with only one discharge (Ekbom, et al., 1994). Pooled analysis from the International 
Pancreatic Cancer Case-control Consortium (PanC4) found that an estimated 1.34% of 
pancreatic cancers where attributable to chronic pancreatitis and that the risk for those 
diagnosed before the age of 65 had twice the risk of those diagnosed after the age of 65 
(Duell, et al., 2012). 
 
3.1.3.3.  Unclear risk effects 
Unclear risk effects are potential risk factors for the development of disease, however 
there is not enough scientific evidence to support the findings and claim that they increase the 
risk of disease.  
 
3.1.3.3.1.  Diabetes Mellitus 
There seems to be a bidirectional relationship between diabetes mellitus and pancreatic 
cancer. Gupta, et al., (2006) found that for patients with new-onset diabetes mellitus, the 
incidence of pancreatic cancer was more than twice as high than for non-diabetics. However, 
only about 0.5% of patients with newly diagnosed diabetes developed pancreatic cancer 
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during a 6-year follow-up, so the absolute risk remains low. A multicenter case-control study 
from China  reported that diabetics where more that twice as likely to develop pancreatic 
cancer (OR = 2.69, 95% CI = 1.51-4.77) than non-diabetics (Zheng, et al., 2016). Wang, 
Herrington, Larsson, & Permert (2003) on the other hand concluded in their review, that new-
onset diabetes had the strongest association with pancreatic cancer and was actually largely 
responsible for the association with pancreatic cancer, and that this might be due to abnormal 
islet cell function. 
 
Thus, there is no clear-cut answer to whether or not diabetes is a direct risk factor for 
pancreatic cancer since diabetes could be sequel to pancreatic cancer and there is no 
overwhelming body of evidence pointing in either direction in terms of causality.  
 
3.1.3.3.2.  Alcohol consumption  
 Evidence is inconsistent regarding alcohol and pancreatic cancer risk; this is largely 
due to the close association between alcohol and smoking which makes it problematic to 
implicate alcohol as an independent risk factor for pancreatic cancer. However, alcohol does 
affect the pathogenesis of pancreatitis indicating that it could promote other risk factors such 
as smoking (Yadav & Lowenfels, 2013).  In a study of never smokers, Gapstur et al observed 
that a consumption of more than 3 drinks of liquor per day increased the risk of pancreatic 
cancer by 32%, whilst the consumption of beer and wine in the same amount did not yield the 





3.1.3.3.3.  Diet  
 Consumption of fat and animal fat in particular has been associated with an increased 
risk of pancreatic cancer regardless of smoking status (Zhang, Zhao, & Berkel, 2005). A high 
intake of the dietary mutagens: PhIP, BaP and MeIQx, has also been associated with a 2-fold 
risk increase of pancreatic cancer (Li, et al., 2007). Meta-analysis has shown that fruit and 
vegetable intake is associated with a reduction in risk of pancreatic cancer (Wu, Wu, Zheng, 
Xu, Ji, & Gong, 2016). 
 
3.1.3.3.4.  Physical activity 
 Physical activity has been suggested to reduce the risk of pancreatic cancer (Inoue et 
al., 2008; Jiao et al. 2009) but due to methodological limitations and inconsistency of the 
evidence this evidence is seen to be very limited (Kruk & Czerniak, 2013). Despite having 
been seen to have positive associations with obesity and elevated blood glucose, physical 





3.1.4.  Treatment and survival 
Treatment for pancreatic cancer depends on the tumor location and if the tumor is 
resectable. Medical consensus is that surgery should be the main form for treatment given a 
low-grade tumor and early stage, if the tumor is unresectable or there are other considerations 
there may be necessary to provide adjuvant chemotherapy to maximize treatment-
effectiveness or to start neoadjuvant treatment before surgery is attempted (Dragovich, 2016). 
Depending on tumor location, the procedures may wary from cephalic 
pancreatoduodenectomy (Whipple procedure) and distal- or total pancreatectomy. Study-data 
from randomized controlled trials’s have shown that more extensive resections is not 
associated with an increased survival, but instead increases the risk of postoperative 
complications and morbidity (Hidalgo, 2010).  
 
For exocrine pancreatic cancers, surgical resection may not be curative but only 
palliative and life-prolonging. Should the patients be diagnosed with a locally or 
systematically advanced disease, then treatment-options is usually palliative care if form of 
surgery or chemotherapeutic medication. Chemo-radiation therapy may also prove useful as a 
part of the total treatment perspective, both in early stages as well as advanced stages of 





3.1.4.1.   Stage and tumor grade – 5-year survival 
In accordance to the World Health Organization’s (WHO) classification and tumor 
grading, the stage of cancer is determined by several factors: if the cancer have metastasized 
to other organs, the size and location of the primary tumor and if there is involvement of the 
regional lymph nodes. Tumor grading is an indication of the growth-rate of the particular 
tumor. Tumors that have not deviated much in appearance from normal tissue cells tend to 
grow and develop slower than those who have clearly differentiated from a normal cellular 
appearance. With exception to a few different types of cancers, tumors are graded from 1-4 
depending on how the abnormal the tumor-cells have become (Damjanov, Fang, 2013).  
 
Because of the poor prognosis of pancreatic cancers, even early stage and low-grade 
tumors will have a mean survival of approximately two years depending on treatment, and 
patients diagnosed with advanced stages will on average only live for 4-10 months as shown 
in Table 1. The 5-year relative survival rates of pancreatic cancer were calculated to be 6,9% 
in 2010 in an epidemiological study by Sun et al, 2014. Data retrieved from the Surveillance, 
Epidemiology and End Results (SEER) registries in the United States of America, showed an 
increase in the relative 5-year survival from 3,1-6,9% over the decades from 1981-2010. 1-
year survival also improved from 17-28,2% during the same time period, and the increased 
survival time could be a result of improved treatment and diagnostic techniques for pancreatic 
cancer patients over the last three decades (Sun et al, 2014). The Cancer in Norway (CIN) 
report of 2015 shows a 5-year relative survival for pancreatic cancer of 6,4% for men and 





Table 1: The World Health Organizations international grading of pancreatic tumors, 
different staging of pancreatic cancer and median survival in months dependent on tumor 
grade and metastasis. 
Stage Tumor Grade Distant Metastases Median Survival  Characteristics 
IA T1 M0 24.1 months The tumor is limited to 
the pancreas and is ≤ 
2cm in dimension.   
IB T2 M0 20. 6 months The tumor is limited to 
the pancreas and is  
> 2cm in dimension.   
IIA T3 M0 15.4 months The tumor have grown 
outside of the pancreas, 
but does not involve the 
celiac axis or the 
superior mesenteric 
artery. 
IIB T1, T2 or T3 M0 12.7 months There is regional lymph-
node-metastasis. 
III T4 M0 10.6 months The tumor involves the 
celiac axis or the 
superior mesenteric 
artery. The tumor is not 
resectable.  
IV T1, T2, T3 or T4 M1 4.5 months The tumor have spread to 
other organs causing 
distant metastasis. 
T: Primary pancreatic tumor. M: Metastasis to other organs. 
 
Source: International Agency for Research on Cancer (IARC), World Health 







3.2. Smoking: Global- and Norwegian prevalence. 
3.2.1.  Introduction to smoking as an exposure 
Smoking continues to be one of the main causes of cancer world-wide. According to 
the World Health Organization (WHO) approximately six million people will annually die 
from smoking-related illnesses and diseases, of which approximately six hundred thousand of 
the total number of deaths will be from exposure to second-hand smoking. Despite an overall 
decreasing prevalence, there seems to be an increase in incidence in the African and the 
Eastern Mediterranean regions of the globe (WHO, 2016).   
 
3.2.1.1.   Global prevalence 
The WHO’s global report on trends in prevalence of tobacco smoking (2015), shows a 
large difference in prevalence among gender, due to large gender differences in low- and 
middle-income countries with men smoking almost five times more than women. Among 
high-income countries and much of the western part of Europe, there is little to no difference 
in the smoking-ratio between gender (Hitchman & Fong, 2010). 
 
Research suggest several reasons for differences in smoking-ratio based on 
demography, but equal gender-rights and empowerment of women may be a reason for the   
similar smoking patterns in the western part of the world (Waldron, 1991). The WHO states 
that the regions of the world that still have gender inequalities in terms of civil rights such as 
certain parts of Africa, Asia, Western Pacific and the Eastern Mediterranean regions have 
lower prevalence of female smokers, while the Western societies that promotes gender 






The Surgeon General’s Report of 2001 on Women and Smoking states that there was a 
higher prevalence of smoking among women with higher education (≥ 8 years of education) 
than among those with lower or none education in middle- to high-income countries (CDC, 
2001). Numbers from the WHO’s global report (2015) show that the highest prevalence of 
women that smoke are in Europe and the American continents, and lowest in Africa and 
South-East Asia. The highest prevalence of smoking among men are in the Western Pacific, 
Europe and Eastern Mediterranean regions as seen in Table 2.  
 
    Source: World Health Organization’s global report on tobacco (2015).
Table 2: The prevalence of tobacco-smoking between gender for WHO regions. 
Prevalence of smoking any tobacco product among any person aged >= 15 years 
of age in 2012 among WHO Regions. 
WHO Region Female Male 
Africa 2,4 24,2 
Americas 13,3 22,8 
South-East Asia 2,6 32,1 
Europe 19,3 39,0 
Eastern Mediterranean 2,9 36,2 
Western Pacific 3,4 48,5 





The WHO’s global report (2015) further examines the trends and prevalence of 
smoking among the 194 member states, and have given estimates for the future prevalence for 
the period 2015-2025. This is part of WHO’s target for combating non-communicable 
diseases (NCD) as a part of their global action plan, lists tobacco smoking as an individual 
target objective. The NCD-goal is to reduce the prevalence of tobacco smoking among adults 
aged > 15 years, by 30%. The report states that if there is a collectively reduction in smoking 
prevalence of 30% among all member states, the level of 22,1% in 2010 would be reduced to 
15,4% by 2025. According to the WHO, this would imply a 14% overall relative reduction in 
smoking. Table 3 shows a global decrease in prevalence percentage for both genders over a 
15-year period, with a 3,7% decrease for males and a 2,6% decrease for females, respectively 
(WHO, 2015). 
 
Table 3: Overview of change in prevalence of current tobacco smoking among regions. 
 
Source: World Health Organization’s global report on trends in prevalence of tobacco 
smoking (2015). 
AFRO: African regions. 
AMRO: American regions. 
EMRO: Eastern Mediterranean Regions. 
EURO: European Regions. 
SEARO: South East Asian Regions. 





3.2.1.2.   Prevalence in Norway. 
The Norwegian Institute of Public Health (NIPH)/Folkehelseinstituttet has reported a 
continuous decrease in the prevalence of smoking among the adult population over the last 
decades and only 13% of the Norwegian population was reported to be a current smoker in 
2014 (NIPH, 2015). This is a 14% decrease since the WHO’s estimate of 27% current 
smokers within the Norwegian population from 2010 (WHO, 2015). There are currently only 
slight differences in male and female smoking prevalence in Norway, and the NIPH reports 
that the prevalence has been decreasing since 1973 for the male population and 2001 for the 
female population, as can be seen in figure 4. The prevalence of occasional smokers has been 
similar for both gender, and approximately steady around 10% since 1972.  
 
Figure 4: Prevalence of smoking in adults (16-74 years) 1972-2013. 





Numbers show that the main age-group of smokers in Norway are those between 45-
64 years (21%), for those younger than 45 and older than 64 years there was only 12-14% 
daily smokers (NIPH, 2015). In the 2010 WHO-estimations, an average of 26,6% of all men 
and 25.2% of all women in Norway were current smokers. The WHO calculated that if 
tobacco control efforts in Norway continue in the current rate, these numbers will have fallen 
with more than 10% for both genders by 2025, as depicted in Table 4. This will have 
decreased the percentage of current smokers to approximately 13,7% and 13,6% for men and 
women respectively (WHO, 2015).  
 




Men Women Total Men  Women Total 
15-24 25.3 25.5 25.4 13.1 13.8 13.4 
25-39 30.0 29.2 29.6 15.5 15.8 15.6 
40-54 30.8 31.1 30.9 15.9 16.8 16.3 
55-69 26.6 24.0 25.3 13.6 12.9 13.3 
70+ 20.6 16.5 18.2 10.6 9.0 9.7 






Data from the Norwegian Bureau of Statistics/Statistisk Sentralbyrå (SSB) show that 
the number of smokers in Norway varies according to counties as shown in figure 4, where 
the numbers of every-day-smokers aged 16-74 years among all Norwegian counties are 
displayed in percentage. In the Norwegian counties study, which covers Finnmark, Sogn og 
Fjordane and Oppland, Finnmark had the highest number of smokers, with almost 20% of the 
inhabitants report to be smoking daily, which also is the highest nationally. Oppland have 
approximately 13% of daily-smokers while Sogn og Fjordane have 12% that reportedly are 
smoking every day (NIPH, 2015). 
 
Figure 5: Number of every-day-smokers across the Norwegian counties from 2008-2015 
measured in percentage. 
 
Source: - Norwegian Bureau of Statistics, Norwegian Institute of Public Health - Statistisk 





3.3.         Pancreatic cancer and smoking: expert reports and recent cohort studies. 
3.3.1.  Introduction to the association between smoking and pancreatic cancer. 
Over the 50 years since the Surgeon General’s report of 1964, the Surgeon General’s 
conclusions are that smoking is greatly involved with health. The reports have been moving 
from a few causal associations in 1964, to the inference of causal relationships between both 
active smoking and the exposure to second-hand smoke in the later reports. The 2004 and 
2006 reports provided a comprehensive coverage of the adverse effects of both active 
smoking and second-hand smoke. The 2010 report addressed the underlying mechanisms for 
the causal relationships which are described in the earlier reports. The 2012 report focused on 
the effects of smoking on the health of children, adolescents, and young adults. The report 
highlighted the association between early life events and subsequent risk for disease. The 
2014 review extended the list of diseases and other adverse health effects of smoking, 
reaffirming the adverse consequences of smoking, and noted that smoking affects nearly 
every organ in the human body.  
 
3.3.2.  The general carcinogenic effects of cigarette smoking. 
 The Surgeon General’s Report (SGR) of 2014 explains the general mechanisms 
behind the exposure to the carcinogens in tobacco smoking and the causation of cancer. 






Nicotine is not considered a chemical carcinogenic, but it is the cause of tobacco 
addiction which in turn leads to prolonged exposure to the carcinogenic chemicals (CDC, 
2014). These chemicals are foreign to the human body and in order to detoxify them, the body 
metabolises them to reactive intermediates which again may cause damage to DNA, leading 
to harmful mutations and cancer growth as illustrated in figure 6, retrieved from the SGR 
(CDC, 2014).    
 









Source: The Health Consequences of Smoking – 50 years of Progress. A Report of the 







































3.3.3.    Overview of recent cohort studies (2013-2017)  
In order to obtain relevant literature for the current study we conducted Boolean 
searches for studies involving the association between pancreatic cancer and smoking 
published in the period of 2013-2017. We conducted searched using search engines from 
PubMed, Cochrane Collaboration and Scopus. We used plain search terminology such as 
pancreatic cancer, cancer pancreas, pancreatic neoplasms, pancreatic adenocarcinoma and 
exocrine pancreatic tumors. We also used Boolean searches with MESH-terms, “pancreatic 
cancer OR pancreatic neoplasms OR cancer pancreas AND smoking”. All searches were 
limited to articles and publications that were published in English. Individual searches were 
conducted by both authors in order to ensure best coverage during the literature search. Since 
the main interest of the study is smoking as a risk factor and not the disease itself we then 
limited ourselves to cohort studies and meta-analysis done with cohort data on the association 
between smoking and pancreatic cancer. 
 
A study from the UK with 7119 pancreatic cancer cases (Hippisley-Cox & Coupland, 
2015) found that male -and female smokers had similar risk increases for all three levels of 
cigarette consumption, light (1-9 per day) moderate (10-19 per day) and heavy (20+) 
compared to never smokers. Heavy smoking had a significant 2-fold risk increase for both 
male –and female smokers. They also reported a slight significant 9% increased risk for male 
former smokers while female former smokers had a non-significant increase of (3%) 
compared with corresponding never smokers.  
 
Another study from Sweden (163 pancreatic cancer cases) (Andersson, Wennersten, 
Borgquist & Jirström, 2015) reported that regular smoking significantly increased pancreatic 
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cancer risk for both men (3-fold increased risk) and women (2-fold increased risk) compared 
to never smokers. The impact of occasional smoking was reported as a significant risk factor 
only for female smokers, with a 3-fold risk increase compared to never smokers. Exposure to 
passive smoke over a long period (<20 years) also yielded a significant risk increase for 
pancreatic cancer for women, who had a 2-fold risk of that of non-exposed.  
 
A Japanese study (611 pancreatic cancer cases) examining the association between 
active and passive smoking and the risk of death from pancreatic cancer in Japan (Lin et al., 
2013) . They found a significant 70% increased risk of pancreatic cancer for current smokers 
compared to never smokers. Unlike that of Andersson, Wennersten, Borgquist & Jirström, 
(2015), they found no significant associations between passive smoke exposure and increased 
pancreatic cancer risk.  
 
In a Swiss study (127 pancreatic cancer cases) on the association between overweight, 
smoking and pancreatic cancer (Meyer et al., 2015) reported an almost 2-fold increased risk 
of pancreatic cancer for high smoking exposure (≥20 cigarettes per day). The study also 
reported that of all deaths, deaths due to pancreatic prostate cancer 29% were attributable to 
ever smoking and overweight combined, respectively. 
 
In a meta-analysis of 19 population-based prospective cohort studies from European 
countries and the USA by Ordóñez-Mena and colleagues (2016) found that current smokers 
had a significant 90% increased risk of pancreatic cancer than that of never smokers. They 
also found that a longer time passed since smoking cessation was significantly associated 
with a decrease in total lung and pancreatic cancer incidence and mortality. After 10 years 
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since smoking cessation, former smokers would have almost 30% less risk than current 
smokers and after 20 years since smoking cessation the risk would be more than halved 
compared with current smokers  
 
Ordóñez-Mena et al (2016) found in their meta-analysis that the duration of smoking 
cessation was associated with a decreased risk of pancreatic cancer. After 10 years since 
smoking cessation, former smokers would have almost 30% less risk than current smokers 
and after 20 years since smoking cessation the risk would be more than halved compared with 
current smokers.  
 
Lin et al (2013) examined the association between active or passive smoking and the 
risk of death from pancreatic cancer in Japan, finding a significant 70% increased risk of 
death from pancreatic cancer for smokers compared with that of never smokers but no 
significant associations between environmental tobacco smoke in public spaces and increased 




Table 5: Expert reports on the association of pancreatic cancer and smoking post 2013.  
a N:Number of study participants. b HR: Hazard Ratio with a 95% Confidence Interval.           
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< 9 years 
10-19 years 

























Adjusted for age 
(continuous, years), sex, 
education level (primary or 
less, more than primary 
but less than 
university/college and 
university or college). 
Vigorously physical 
activity (yes/no), history of 
diabetes mellitus (yes/no), 
BMI (continuous, kg/m2) 
and daily alcohol intake 
(continuous, grams/day). 
In MORGAM Finland and 
Sweden Cohorts, physical 
activity was not available 
and therefore not adjusted 
for.  
a N:Number of study participants. b HR: Hazard Ratio with a 95% Confidence Interval.           










4. Materials and Methods. 
 
4.1. Study population  
 The study population used for this Master thesis is comprised of Norwegian men and 
women that were born between 1905 and 1968, which were recruited for a prospective cohort 
study that was divided into three study periods. A total of 93 946 participants was included in 
the cohort. For this thesis, the following exclusion criteria was applied: any participant that 
had missing information on vital status (n = 11), had other prevalent cancers present (n =719), 
death or emigration before follow-up (n = 39) of which 27 participants had died and 12 
emigrated, smoking status (n = 4354), body mass index (n = 3641), level of physical activity 
(n = 30) and educational level (n = 1652) was excluded from this dataset. This left 83 500 
Norwegian participants (41 587 women and 41 913 men) that was eligible to use in this 
cohort. Among these participants there was a total of 485 cases in which a participant was 
diagnosed with pancreatic cancer, and the remaining 83 015 participants was regarded as non-




Figure 7: Flowchart of exclusion criteria used to select the study participants. 
Entire 3-county study cohort. 
n= 93.946
Exluded due to: 
No vital status reported : 11
Other prevalent cancers present : 719
Death or emigration occured before follow-up :39










4.1.1.  The Norwegian counties study 
The Norwegian counties study (NCS) was a Cohort study conducted from 1974 to 
1988 in the counties of Finnmark, Sogn og Fjordane and Oppland and was developed because 
of the Oslo-survey in 1972 which revealed cardiovascular risk factors among males aged 20-
49 years. The Norwegian Counties Study aimed to reduce to mortality from cardiovascular 
diseases through documentation of potential risk factors and intervention (NIPH, 2015). 
 
The study was divided into 3 screening periods; 1974-1978, 1977-1983 and 1985-
1988. Attendance for the study was 88% for the 1st and 2nd period, and 84% for the 3rd (Stocks 
et al, 2010; Tverdal et al, 1989; Tverdal & Bjartveit, 2006). During the first screening period, 
men and women born between 1925-1927 and 1939-1941 was invited to participate. The 
study later invited everyone born in these time-periods (aged 35-49 years) to participate, as 
well as a selection of men and women aged 20-34 years (10% of the general population). 
Previous participants were also invited to the following two screening periods which also 
included new participants. The response rate for each of the counties first study period was: 
82,4%, 90,1% and 89,8% for Finnmark, Sogn og Fjordane and Oppland counties, 
respectively, minimizing the risk of non-response bias. The screening was conducted in Sogn 
og Fjordane during the periods 1975-1976, 1980-1981 and 1985-1986, in Oppland during 
1976-1978, 1981-1983 and 1986-1988, and in Finnmark during 1974-1975, 1977-1978 and 






Figure 8: Timeline of the Norwegian Counties Study’s three survey periods, for Finnmark, 













Sogn og Fjordane 
1975-76 














4.1.2  Exposure information 
The questionnaire used for the counties study regarding was comprised of 8 main 
question categories labelled A-G, with sub-questions in the first two surveys (Appendix 1). 
One questionnaire was used for Finnmark county and a separate was used for Oppland- and 
Sogn og Fjordane. The questions included own medical history and medication, symptoms, 
exercise, smoking, education/employment status, hereditary factors and questions linked 
directly to cardiovascular hereditary factors. Smoking status had questions that asked about 
smoking habits in terms of daily smoking, former smoking or never smoking.  
 
Participants were also asked to answer number of cigarettes smoked per day, total 
smoking duration and packs per week. For former smokers, the questions revolved around 
time since smoking cessation and previous smoking habits. Participants who reported being 
either current or former smokers were asked also to report their smoking initiation age, for 
how long they had been smoking and total number of cigarettes smoked per day. 
 
Physical activity was categorized into four groups based on what level of activity they 
reported at enrolment to the study. Sedentary (reading, watching television or other sedentary 
activities), Light (walking or bicycling more than 4 hours a week), Moderate (light sports or 
heavy gardening) and Heavy (hard exercise, competitive sports regularly). We collapsed the 
light and moderate level and created a three categoric variable comprising of sedentary, 




BMI was divided into four categories (underweight, normal weight, overweight and 
obese) where normal weight and underweight was collapsed into one variable, due to few 
participants reporting to be underweight. Level of education was categorized into three 
categories; Low (less than 10years of education), Moderate (10-12 years of education) and 
High (equal to or more than 13 years of education). The selected variables are described with 
score range and response options, as shown in Table 6. 
 
Table 6: Description of variables showing score range and response options for all levels of 
the selected variables. 
Variable name Range Level 1 Level 2 Level 3 Level 4 





Age at smoking 
initiation 









smoked per day 
1 – 3  ≤ 5 cig/day 6-15 cig/day ≥ 16 cig/day  
Total years of 
smoking 




≥ 21 years’ 
duration 
 
Physical activity 1 – 4 Sedentary Light Moderate Heavy 
Body mass index 1 – 4   15 - 18,49 18,5 – 24,49 24,5 – 29,99 + 30 
Years of 
education  





4.1.3  Follow-up and Endpoints 
The Norwegian Counties Study followed the participants using personal identification 
number to locate them through the Norwegian Central Population Register (Folkeregisteret), 
the Norwegian Cancer Registry (Kreftregisteret) and the Norwegian Cause of Death registry 
(Dødsregisteret), in order to obtain accurate information about cancer cases, diagnosis, 
emigration or time of death (Bjerkaas, 2014). 
 
Stage of pancreatic cancer at the time of diagnosis or any treatment the participant was 
undergoing during the study time was not considered. The endpoint was defined as either 
being diagnosed with cancer, death or emigration. For all other participants, the end of follow-
up was set at 31st December 2013. The outcome of interest was the diagnosis of pancreatic 
cancer among the study participants.  
 
Pancreatic cancer was defined by the Norwegian Directory of Health’s (NDH) ICD-10 
classification in terms of tumor in the pancreatic head segment (caput pancreatic), body 
segment (corpus pancreatis) and tail segment (cauda pancreatis), the exocrine ducts of the 
pancreas, overlapping tumor growth in pancreatic tissue and unspecified pancreatic 
tumor/cancer (NDH, 2015). This study does not differentiate between exocrine- and 
neuroendocrine tumors (NETs) when it comes to determining the outcome of pancreatic 
cancer being present or not present, but any pancreatic cancer type listed above is considered 





Table 7: ICD-codes used for the determination of pancreatic cancer among the study 
population. 
ICD- Classification Type of malignant tumor in the pancreas 
C250 Malignant tumor in the head-segment of the pancreas 
C251 Malignant tumor in the body-segment of the pancreas 
C252 Malignant tumor in the tail-segment of the pancreas 
C253 Malignant tumor in the pancreatic exocrine ducts 
C257 Malignant tumor in other specific parts of the pancreas 
C258 Overlapping malignant tumors in the pancreas 
C259 Malignant tumor in the pancreas, unspecified 






4.2. Statistical analysis 
Cox proportional hazards model was used with total follow-up time as the underlying 
time scale to estimate age-adjusted- and multivariate hazard ratios with a 95% confidence 
intervals (CI) for the association between smoking status (never, former, current), and 
pancreatic cancer. Separate age-adjusted and multivariate analysis, adjusted for; age at 
enrolment, education level, body mass index and physical activity level, were also conducted 
investigating if there was a dose-response relationship between smoking and pancreatic 
cancer risk, comparing never smokers to different levels of exposure; age of smoking 
initiation (≤19, 20-24, ≥25), number of cigarettes per day (≤5, 6-15, ≥16), duration of 
smoking in years (1-10, 11-20, ≥21), and number of pack years, calculated as a dose of 20 
cigarettes each day, multiplied by the number of years smoking (0-5, 6-15, ≥16). 
 
 Entry time was defined as the age at enrolment and the exit time was whichever 
occurred fist; age at exit, the date of incident cancer diagnosis, emigration, death or the end of 
follow-up (31 December 2013). Independent t-tests were implicated to investigate intergroup 
variance for groups; pancreatic cancer cases and non-cases, and smokers and never smokers 
for all covariates (age at enrolment, education level, body mass index, physical activity level 
and smoking status), for the follow-up time, a Mann-Whitney 2-sample test was used. All 





Tests for linear trend were conducted for all levels of smoking exposure including the 
reference category. Linear trends were obtained by using both categorical and scale variables 
using never smoker as a reference for all groups. All analyses were conducted with the use of 
SPSS version 24 (IBM) 
 
4.2.1.  Confounders  
The possible confounders that were included in the final models were age at enrolment 
(continuous), due to the established increased risk of cancer by advancing age (White et al, 
2015), years of education (categorical: <10, 10-12, ≥13) as greater education can be 
associated with both never and former smoking (Chapman, Fiscella Duberstein, Kawachi, 
2009), body mass index (categorical: normal, overweight, obese) was included due to 
associations with increased pancreatic cancer risk (Genkinger et al, 2011; Genkinger et al, 
2015). and level of physical activity (categorical: sedentary, moderate, heavy) which has been 











     5. Results   
 
During the Counties-Study’s 39-year follow-up period, 485 incidence cases of 
pancreatic cancer where recorded. The overall incidence among men and woman was 256.5 
per 100.000 and 259.7 per 100.000 respectively. Among the study population (N= 83500) 
64.2% reported being either current or former smokers (74% of all men and 54.2% of all 
women). 
  
Table 8 presents the selected descriptive characteristics from the Norwegian Counties 
Study. The majority of the study population (64%) reported being either active or former 
smokers. On average the smoker included in the study started smoking at the age of 21 and 
had an average consumption of 12 cigarettes per day within a 17 year (median) smoking 
period (10 pack years mean). The participants that reported being a current smoker accounted 
for 45,7% of the total study population (39,7% of all women, 51,1% of all men) and former 
smokers accounted for 18,7% (14,6% of all women and 22,9% of all men), the remaining 
35,8% reported being never smokers (45,8% of all women and 26% of all men).  
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 Table 8: Descriptive characteristics from the Norwegian Counties Study, among 83,500 
Norwegian men and women at enrolment (1974-2013). 
 
a Light activity level is defined as “walking, bicycling and other activities at least 4 hours per 
week”. b Ever smokers include former and current smokers. 
 
Table 9 presents the selected characteristics by smoking status at enrolment with 
corresponding p-values from independent t-tests. Smokers were overly represented in the 
male population with as many as 74% reporting either being active or former smokers. Male 
smokers were generally less educated, but generally more active than those that reported 
never smoking. For female smokers, the distribution between smokers and never smokers 
were more even 54% and 46% respectively. Female smokers were generally leaner, but unlike 
male smokers they had similar physical activity level and education levels as their never 
smoking counterparts.  
 
 
Descriptive characteristics N = 83500 
Study period 1974-1987 
Age , ?̅? mean, SD 39 ± 7 
Year of birth, median (range) 1939 (1905-1968) 
Year at pancreatic cancer diagnosis, ?̅? mean, SD 67 ± 9 
Follow-up years, median 32 
Years of education, mean level 10-12 years 
Body mass index , ?̅? mean (kg/m2) 24 
Level of physical activity, mean level Light a 







Age at start smoking, mean age 
Total years of smoking, median 
Number of cigarettes smoked per day, ?̅? mean 








From the result of independent t-test, we found that there was a statistically significant 
difference in the variances between ever and never smokers in all groups of covariates for 
both male and female participants at the critical significance level of 0.05 as shown in Table 
9.  
 
Table 9: Selected characteristics of the study population at enrolment in the Norwegian 
Counties Study (N = 83500) by smoking status. 
 Ever smoker Never smoker pa 
Men N = 41 913 (%) 31 015 (58) 10 898 (36)  
Follow-up time, median (IQR)b 30 (26-37) 33 (27-37) < 0.001 
Age at enrolment (mean year) 40 38 < 0.001 
Age at diagnosis (mean year) 66 65  
Years of education (%) 
< 10 years 
10-12 years 










Body mass index (kg/m2) (%) 
WHO group 1-2 
WHO group 3 























    
Women (N = 41 587) 22 555 (54) 19 032 (46)  
Follow-up time, median (IQR)b 32 (27-37) 36 (27-37) < 0.001 
Age at enrolment (mean year) 39 40 < 0.001 
Age at diagnosis (mean year) 67 69  
Years of education (%) 
< 10 years 
10-12 years 










Body mass index (kg/m2) (%) 
WHO group 1-2 
WHO group 3 























a The p-value are from t-test or χ2 test for difference between the participants with and 
without pancreatic cancer. b The p-value are from Mann-Whitney 2-sample test/Wilcoxon test. 
c The levels of physical activity is defined as; Sedentary (reading, watch television, other 
sedentary activity), Moderate (walking, bicycling and other activity > 4 hours per week), 





Table 10 displays the selected characteristics by pancreatic cancer status. Participants 
with pancreatic cancer were predominantly smokers (86% men 66% women). Female never 
smokers comprised 34% of all female pancreatic cancer cases, while male never smokers only 
comprised 14% of the male pancreatic cancer cases. Male and female cases did however not 
differ much in terms of age, BMI, education and physical activity and both male and female 
cases received their diagnosis at similar ages (mean 66 and 67 years respectively).  
 
From the result of independent t-test, we find that for pancreatic cancer cases and non-
cases there is no statistically significant difference in the variances between cases and non-
cases in any group of covariates BMI, education or physical activity for male smokers, nor 
any statistically significant differences in covariates education or physical activity for female 






Table 10: Selected characteristics of the study population at enrolment in the Norwegian 
Counties Study (N = 83500) for the participants with and without pancreatic cancer, sorted by 
sex. 





Men (N = 41 913) 241 41642  
Follow-up time, median (IQR)b 25 (18-30) 31 (26-37) < 0.001 
Age at enrolment (mean year) 39 41 < 0.001 
Age at diagnosis (mean year) 66   
Years of education (%) 
< 10 years 
10-12 years 










Body mass index (kg/m2) (%) 
WHO group 1-2 
WHO group 3 

































    
Women (N = 41587) 244 41343  
Follow-up time, median (IQR) 26.5 (20-33) 33 (27-37) < 0.001 
Age at enrolment (mean year) 42 39 < 0.001 
Age at diagnosis (mean year) 67   
Years of education (%) 
< 10 years 
10-12 years 










Body mass index (kg/m2) (%) 
WHO group 1-2 
WHO group 3 

































a The p-value are from t-test or χ2 test for difference between the participants with and 
without pancreatic cancer. b The p-value are from Mann-Whitney 2-sample test/Wilcoxon test. 
c The levels of physical activity is defined as; Sedentary (reading, watch television, other 
sedentary activity), Moderate (walking, bicycling and other activity > 4 hours per week), 
Heavy (light sports, heavy gardening etc. and hard exercise, competitive sports regularly).   
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Table 11 presents the age adjusted and multivariate hazard ratio (HR) estimates with 
95% confidence intervals (CIs) for pancreatic cancer by smoking status and exposure 
variables (age at smoking initiation, number of cigarettes per day, total years of smoking and 
pack-years) for men and women respectively. 
 
In the age adjusted analysis, smoking was associated with a significantly greater risk 
of pancreatic cancer compared with never smokers for both men (HR = 2.54, 95% CI = 1.92-
3.34) and women (HR = 2.44, 95% CI = 1.68-3.54). Compared with never smokers, men that 
reported having been smokers previously, but had quit smoking (no exact quitting date) had a 
62% (HR = 1.62, 95% CI = 1.05-2.49) increased risk while women in the same group showed 
only a non-significant 15% risk increase (HR = 1.15, 95% CI = 0.73-1.80) compared with 
never smokers.  
 
For both male –and female smokers the age and multivariate hazard ratios were 
similar. Both male -and female ever smokers had significant increased risk of pancreatic 
cancer compared with never smokers in all exposure categories with the exception of those 
smoking less than 5 cigarettes per day.  
 
In the multivariate analysis, we found a close to 3-fold increase in risk of pancreatic 
cancer when comparing male smokers in the highest exposure category for all exposure 
variables with never smokers. While female smokers had just above 3-fold increase in risk of 
pancreatic cancer compared with never smokers. Compared with never smokers, male 
smokers had similar associations for those who reported age start smoking ≤ 19 years (HR = 
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2.81, 95% CI = 1.87-4.20), more than 21 years of smoking (HR = 2.82, 95% CI = 1.87-4.24) 
and more than 16 pack years (HR = 2.80, 95% CI = 1.84-4.24).  
 
Compared with never smokers, female smokers also showed similar association 
between exposure and risk of pancreatic cancer. Age at start smoking ≤19 years of age (HR = 
3.28, 95% CI = 2.22-4.82), more than 16 pack-years (HR = 3.23, 95% CI = 2.02-5.14), 
number of cigarettes per day (HR = 3.14, 95% CI = 1.90-5.19) and ≥21 total years of smoking 
(HR = 3.08, 95% CI = 2.12-4.45).  
 
 The tests for linear trend across the different exposure categories for age at initiation, 
number of cigarettes per day, smoking duration, and pack-years also shown in Table 11 show 
that all reported trends where statistically significant (Ptrend < 0.05) for female participants. 
For male participants, there was no observed linear trend for any of the exposure categories 
(Ptrend > 0.05 for all categories).   
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Table 11: Age adjusted and multivariate hazard ratios (HRs) and 95% confidence intervals 
(CIs) for pancreatic cancer cases a by sex, including selected covariates, tested for linear 
trends. 
 
a For pancreatic cancer cases (n = 83 500 with 485 cases). b Cases of pancreatic cancer for 
multivariate analysis. c Total number of years smoking. d Ever smoker defined as former and 
current smokers combined. e One pack having 20 cigarettes: number of cigarettes smoked 
daily multiplied with the number of years smoking. 
Multivariate analysis adjusted for; age at enrolment, education, body mass index and 
level of physical activity. 
  
Smoking exposure Men Women 
Casesb 
(%) 
HR 95% CI 
age adjusted  




HR 95% CI  
age adjusted 
HR 95% CI 
multivariate 
Never smoker 34 (14) Ref. Ref. 82 (33) Ref. Ref. 
Former smoker 54 (22) 1.62 (1.05-2.49) 1.66 (1.07-2.54) 25 (10) 1.15 (0.73-1.80) 1.16 (0.74-1.81) 
Current smoker 153 (63) 2.54 (1.92-3.34) 2.61 (1.78-3.80) 137 (56) 2.44 (1.68-3.54) 2.50 (1.89-3.31) 
Ever smoker d 207 (86) 2.16 (1.50-3.10) 2.24 (1.55-3.23) 162 (66) 2.14 (1.63-2.79) 2.10 (1.60-2.75) 
       
Age start smoking 
≥25 years 
20-24 































≤ 5 cig/day 
6-15 cig/day 



























Ptrend: < 0.001 








































































There are not many studies that examine the differences between male and female 
smokers in relation to pancreatic cancer risk. Our study is one of few studies done on the 
association between smoking and pancreatic cancer risk in Norway and to our knowledge the 
first to find a linear dose-response relationship between exposure level and pancreatic cancer 
risk for female smokers. Our study shows that both male and female smokers have an 
increased risk of pancreatic cancer compared with never-smokers. The risk was of the same 
magnitude and had overlapping confidence intervals. The risk of pancreatic cancer was 
greater for current smokers than for former smokers for both males and females. Furthermore, 
our study shows that female smokers have a dose-response relationship between the different 
measures of smoking exposure and increased risk of pancreatic cancer, which was not evident 
for male smokers. In our multivariate analysis, the overall smoking associated risk of 
pancreatic cancer compared with never smokers for both sexes were similar to that of the age 
adjusted analysis, indicating only a minor modification from the addition of covariates; 
education level, body mass index and physical activity level to the model. 
 
Our results are consistent with previous findings that there is an increased pancreatic 
cancer risk for smokers compared with never smokers. (Bosetti et al, 2012; Schulte et al, 
2014; Lynch et al, 2009). Previous studies have also found a dose-response relationship 
between the association between different levels of smoking exposures and pancreatic cancer 
risk (Zou et al, 2014; Iodice et al; Hippisley-Cox & Coupland, 2015; Meyer et al, 2015). More 
support for the results is found in the carcinogenic effects of smoking (CDC, 2014). Our study 






pancreatic cancer risk for male smokers, consistent with the findings from earlier 
meta-analysis (Zou et al,. 2014). However, opposite that of Zou et al (2014) our study found 
that there is a linear dose-response relationship between smoking and PC risk for female 
smokers for initiation age, intensity, duration and cumulative amount (pack-years).  
 
6.1. Gender differences in smoking related pancreatic cancer 
 We found that women have a dose-response related risk for pancreatic cancer across 
all exposure covariates (age at initiation, cigarettes/day, total years of smoking and 
packyears). Although the incidence rate for pancreatic cancer in Norway is evenly distributed 
between men and women, and the increased pancreatic cancer risk is similar for both male 
and female smokers, only female smokers showed a dose-response relationship 
 
In the heaviest exposure categories, female smokers showed a three-fold increase in 
risk from early initiation (≤ 19 years old), high consumption (≥16 cigarettes per day), and 
long smoking duration (≥21 years) compared with never smokers. We found that in the 
heaviest categories, the risk of pancreatic cancer was 3-folded among women and nearly 3-
folded for men.  
 
The differences in exposure based risk between male and female smokers might be 
explained by interactions of genes and smoking (Duell et al, 2002) or an increased 
susceptibility to tobacco carcinogens in women, as has been suggested to be the case for lung 
cancer (International Early Lung Cancer Action Program Investigators, 2006; Papadopoulos 





6.2. Strengths and limitations to the study 
6.2.1.  Strengths 
The strengths of the study are that it is a large prospective cohort containing a large 
proportion of both male and female smokers from geographically separated populations in 
Norway. The cohort’s long follow-up period gives more stable risk estimates, smoking history 
was accessed at enrolment, minimizing the risk of recall bias.  
 
The Norwegian Counties study shows a total mortality within the study population 
(the counties of Oppland, Sogn- og Fjordane and Finnmark) that is similar for that of the total 
national mortality (Vollset, Selmer, Tverdal, & Gjessing, 2006). Therefore, we assume that 
the current study holds good external validity for the whole of the Norwegian population. It 
must also be considered a strength of the study, that the cohort has as many as 485 incidence-
cases of pancreatic cancer. This number is relatively high considering the Surgeon General 
(2014) only presented two cohort studies, one including 355 (Dandona et al, 2011) and the 





6.2.2.  Limitations 
 The study has several limitations. The current study has no information on alcohol 
consumption, which might modify the sex-differences in that Norwegian men have higher 
alcohol consumption than Norwegian women (Strand & Steiro, 2003), as alcohol may 
increase the risk of pancreatic cancer (Gapstur, Jacobs, Deka, McCullough, Patel, & Thun, 
2011). 
 
Information concerning occasional smoking, second-hand smoke, diabetes mellitus 
history as well as any history of hereditary cancer is also missing and can therefore not be 
adjusted for. Lack of information regarding occasional smoking and second-hand smoke 
exposure could lead to biased results since 10% of Norwegians are occasional smokers (Lund 
& Lindback, 2007). These individuals are likely to be included in the reference group.  
 
Risk estimates on smoking might also be tainted, i.e. current and former smokers 
might be misleading since participants reporting being current smokers at enrolment might 
stop smoking during the follow-up period, and former smokers might start smoking again. 
This will influence the risk estimates in that the true estimates for a pure current smoker group 
would lie somewhat higher and pure former smoker group would lie somewhat lower than our 







6.2.3.  Internal validity  
 Internal validity is defined as the extent to which a causal conclusion based on the 
study is warranted. Internal validity depends on both systematic and random error i.e. 
confounding and bias, thus the internal validity is thus determined by the degree to which the 
study minimizes bias. Internal validity is evaluated by whether the observed changes in the 
outcome measure, in this case pancreatic cancer risk can be attributed to the main exposure, 
and not to other factors.  The representativeness of the study population or lack thereof is one 
of the largest factors concerning internal validity.   
 
6.2.4.  External validity 
External validity refers to the validity of generalized inference i.e. to what extent the 
results can be generalized to other populations then the sample used in the study (Bonita, 
Beaglehole, & Kjellstrom, 2006). Due to the fact that our data is collected in Norway, 
although representative for a random sample of the Norwegian population, it can be difficult 
to generalize our study results to a wider European population (NIPH, 2015). We assume that 
our results can be generalized to the Western Causation population as done in previous studies 
(Parajuli, 2014). At the time of data-collection (Norwegian Counties Study), the Norwegian 
prevalence was somewhat higher, as the prevalence for males peaked (65%) in the late 







6.2.5.  Random error 
 Random error might occur because the estimates we produce are based on samples, 
and these samples may not accurately reflect the population at large. Random error might 
therefore lead to non-reproducibility of the study results, weakening the association between 
the exposure and the outcome. Thus, a larger sample size gives increased precision to a study.  
Our study was of a large prospective cohort containing a large proportion of both male and 
female smokers from a geographically separated population in Norway, minimalizing the 
sampling error and thus increasing the precision (Bonita, Beaglehole, & Kjellstrom, 2006).  
 
Random error issues are also addressed in terms of the statistical procedures used in 
our study. Our hypothesis was tested at the 5% level and 95% confidence intervals are 
calculated for all the analysis.  
 
6.2.6.  Systematic error 
Systematic error or “Bias” is used to describe a deviation of the result that on a 
systematic level differentiates from the truth. This can be further defined as an error that 
affects the design, method of collection, interpretation, analysis, publication or review that 
leads to a result that is untrue (Porta, 2014). The measurements involving body mass index 
(BMI) might be flawed i.e. measurements conducted at different times and places open for 
information measurement error. This might be due to differences in equipment used for the 
measurements, or human error e.g. reading or reporting the wrong measurements for height or 
weight etc. For all questionnaire based surveys we will not know whether participants under- 
or over reports certain aspects of their lifestyle related activities e.g. physical activity or 




 Non-response bias occurs when the response of the participants varies from the 
potential response of those who did not participate in the study. This might lead to under- or 
overreporting. The reason for under- or over reporting might also be due to recall bias i.e. 
participants might not fully remember, or forget some of the information regarding smoking 
exposure or age at initiation etc. (Finchman, 2008). We have no reason to assume that this 
will differ according to our reported cases and non-cases, as the Norwegian Counties Study 
was designed to examine risk factors for cardiovascular disease and not pancreatic cancer. 
 
 Selection bias occurs when there is a systematic difference between the characteristics 
of the people selected for a study and the characteristics of the people who are not. Selection 
bias usually occurs if there is an aspect of self-selection involved, i.e. the participants are 
allowed to choose the study they want to join. If subjects are allowed the choice, certain 
personality traits seem to encourage study participation. Thus, any result might be due at least 
in part by the differences in characteristics between participants and non-participants (Katz, 
Elmore, Wild, & Lucan, 2013).  
 
6.3.   Implications for Public Health 
 The prevention of pancreatic cancer should be considered a public health issue, given 
the poor prognosis of the disease and limited treatment options. Most of the patients 
diagnosed with this disease will not benefit effectively from surgery or chemotherapy. This is 
reflected in the poor 5-years survival rates. Prevention should be considered equally or more 
important than the treatment. The efforts of prevention may prove to be far costlier than the 
treatment-options, but could decrease the current incidence-rates. Our study found that 
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smoking was the most significant risk factor for the development of pancreatic cancer given 
the available exposure variables in our study.  
 
The prevention of exposure from tobacco smoking should be a key factor in the 
prevention of this cancer type, as approximately 20-30% of all pancreatic cancer cases can be 
contributed to smoking (Tranah, Holly, Wang, Bracci, 2011). Working towards the World 
Health Organization’s NCD-goal of 2025 should be prioritized in order to achieve a 30% 
decrease in prevalence among smokers, and reduce future cases of pancreatic cancer and other 
smoking-related diseases.   
 
Tobacco-control and preventive measures should further be enforced in society, as 
smoking is one of the most significant modifiable risk factor for many diseases. Smoking 
cessation should be encouraged and further restrictions to public smoking should be applied in 
order to prevent harm.  
 
6.4.  Suggestions for further research 
Our findings suggest that the carcinogenic effects of smoking may be more hazardous 
for women in terms of pancreatic cancer risk, which highlights the importance of taking 
potential sex differences into consideration in further studies and prevention efforts. Our study 
does not include alcohol consumption, a factor that could influence the effect of smoking on 




We lacked detailed information on smoking cessation but found that current smokers 
had higher risk estimates than former smokers, though estimates for female former smokers 
were non-significant compared with none smokers. Further research on the effects of smoking 
cessation between genders might therefore be warranted in larger cohorts with higher number 













The main aim of this thesis was to examine the association between smoking and the 
risk of pancreatic cancer. Our study found in accordance to similar previous research that 
there is a significant increased risk of pancreatic cancer associated with smoking. We also 
found that female smokers have a statistical significant dose-response relationship between 
smoking and pancreatic cancer risk, which was not present for male smokers. The dose-
response relationships for female smokers were revealed for all the exposure variables (age at 
smoking initiation, number of cigarettes per day, total years of smoking and pack-years) 
examined in our analysis. We found similar results for both the age-adjusted and multivariate 
analysis, indicating no modification by the covariates (education level, body mass index and 
physical activity level) on the effect of smoking on pancreatic cancer risk.  
 
All cohort-studies published between January 2013 to February 2017 on the 
association between smoking and pancreatic cancer risk, are in consensus with our study that 
there is a causal relationship between smoking and the risk of pancreatic cancer. This is also 
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Appendix 1:  
- Questionaire used in the Norwegian Counties Study: Finnmark County. Round 1 and 
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Appendix 1. Questionaire used in the Norwegian Counties Study: Finnmark County. Round 1 
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Appendix 2. Final report from the Norwegian Counties Study: report from each county in 
each survey (1974-78, 1977-83 and 1985-88), Finnmark, Sogn og Fjordane and Oppland 
counties.  
 
